How we diagnose and treat systemic mastocytosis in adults (Q47763014)

5 February 2018

title

How we diagnose and treat systemic mastocytosis in adults (English)

1 reference

5 February 2018

main subject

systemic mastocytosis

1 reference

Robyn M Scherber

1

1 reference

5 February 2018

Uma Borate

series ordinal

2

1 reference

5 February 2018

language of work or name

English

0 references

publication date

19 October 2017

1 reference

5 February 2018

British Journal of Haematology

published in

1 reference

5 February 2018

volume

180

1 reference

5 February 2018

issue

1

1 reference

5 February 2018

page(s)

11-23

1 reference

5 February 2018

Successful treatment of mast cell activation syndrome with sunitinib.

cites work

1 reference

Successful targeted treatment of mast cell activation syndrome with tofacitinib

21 January 2018

1 reference

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

21 January 2018

1 reference

Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis.

21 January 2018

1 reference

Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin.

21 January 2018

1 reference

21 January 2018

1 reference

Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients

21 January 2018

1 reference

Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder

21 January 2018

1 reference

Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.

21 January 2018

1 reference

Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.

21 January 2018

1 reference

Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes

21 January 2018

1 reference

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis

21 January 2018

1 reference

The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease

21 January 2018

1 reference

Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay

21 January 2018

1 reference

Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine

21 January 2018

1 reference

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.

21 January 2018

1 reference

Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome

21 January 2018

1 reference

The role of the mast cell in clinical gastrointestinal disease with special reference to systemic mastocytosis

21 January 2018

1 reference

A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib

21 January 2018

1 reference

Reports of Medical and Surgical Practice in the Hospitals of Great Britain

21 January 2018

1 reference

Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival

21 January 2018

1 reference

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

21 January 2018

1 reference

Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta-analysis

21 January 2018

1 reference

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

21 January 2018

1 reference

Treatment strategies in mastocytosis

21 January 2018

1 reference

Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease.

21 January 2018

1 reference

Mast Cells, Mastocytosis, and Related Disorders

21 January 2018

1 reference

Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia

21 January 2018

1 reference

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.

21 January 2018

1 reference

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

21 January 2018

1 reference

Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.

21 January 2018

1 reference

Diagnostic criteria and classification of mastocytosis: a consensus proposal

21 January 2018

1 reference

Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression

21 January 2018

1 reference

Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal

21 January 2018

1 reference

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components

21 January 2018

1 reference

Mast cell-mediated and associated disorders in pregnancy: a risky game with an uncertain outcome?

21 January 2018

1 reference

Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha

21 January 2018

1 reference

A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy

21 January 2018

1 reference

Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.14967

1 reference

5 February 2018

1 reference

5 February 2018